{"title":"QUANTITATIVE IMMUNOFLUORESCENCE EVALUATION OF PD-L1 EXPRESSION IN NON-MUSCLE-INVASIVE AND MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER","authors":"T.A. Bogush, K.S. Spiridonova, E.A. Bogush, A.N. Grishanina, A.M. Scherbakov, M.I. Volkova, Z.M. Safarov, V.B. Matveev, V.S. Kosorukov","doi":"10.55959/msu0579-9384-2-2023-64-6-559-567","DOIUrl":null,"url":null,"abstract":"The expression of PD-L1 protein was quanti ed in 56 samples of urothelial bladder cancer (BC). PD-L1 expression was detected in all BC samples, while in non-muscle-invasive bladder cancer (NMIBC) the median value is 1,5 times higher than in muscle-invasive bladder cancer (MIBC) (p = 0,001). High PD-L1 expression level (≥30%) was observed in 20% of MIBC samples and among NMIBC tumors - in 68% of cases, that is 3,4 times more often (p = 0,0004). The last fact justi es the prospect of starting therapy with immune checkpoint inhibitors already at the onset of the disease - at NMIBC.","PeriodicalId":23660,"journal":{"name":"Vestnik Moskovskogo Universiteta Seriya 2 Khimiya","volume":"356 7","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vestnik Moskovskogo Universiteta Seriya 2 Khimiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55959/msu0579-9384-2-2023-64-6-559-567","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The expression of PD-L1 protein was quanti ed in 56 samples of urothelial bladder cancer (BC). PD-L1 expression was detected in all BC samples, while in non-muscle-invasive bladder cancer (NMIBC) the median value is 1,5 times higher than in muscle-invasive bladder cancer (MIBC) (p = 0,001). High PD-L1 expression level (≥30%) was observed in 20% of MIBC samples and among NMIBC tumors - in 68% of cases, that is 3,4 times more often (p = 0,0004). The last fact justi es the prospect of starting therapy with immune checkpoint inhibitors already at the onset of the disease - at NMIBC.